Women More Likely to Shift Toward Cannabis After Legalization
Healthcare provider explaining cannabis oil to female patient
A Canadian study found meaningful changes in cannabis and antidepressant use after national legalization, especially among women. Researchers analyzing Ontario data from 2013 through 2023 found cannabis only use increased from 7.2 percent to 14.9 percent, while combined cannabis and antidepressant use rose from 1.3 percent to 5.5 percent. Women also showed a stronger shift toward cannabis use relative to antidepressant use after legalization. The findings do not prove that cannabis replaced prescribed treatment or that legalization caused individual patients to stop antidepressants, but they raise important questions around medication interactions, patient education, clinical guidance, product claims, and responsible cannabis access.
Quick facts
• Researchers analyzed Ontario data collected from 2013 through 2023
• The study included 20,498 adults age 18 and older
• About 52 percent of study participants were women
• Cannabis only use increased from 7.2 percent before legalization to 14.9 percent after legalization
• Combined cannabis and antidepressant use increased from 1.3 percent to 5.5 percent
• Women showed a higher relative likelihood of cannabis use compared with antidepressant use after legalization
• Combined cannabis and antidepressant use increased among both women and men
• The research was observational and does not prove that legalization caused individual patients to replace antidepressants with cannabis
• Cannabis can interact with prescription medications, and Health Canada advises patients to discuss cannabis use with healthcare professionals
• The universal operator lesson is simple: when legal access changes consumer health behavior, product education, clinical boundaries, responsible claims, and patient safety become more important
If changing patient behavior around cannabis and mental health is affecting your business plan, complete our quick Puro Risk intake form so you can map product claims, patient education, compliance, clinical relationships, and insurance exposure before health related positioning creates a larger operating problem.
Why this research matters
Canada legalized nonmedical cannabis nationally in 2018, creating an opportunity for researchers to examine how consumer behavior changed before and after legal access expanded.
The Ontario study looked at four broad patterns: cannabis use without antidepressants, antidepressant use without cannabis, use of both, and use of neither.
Researchers found substantial growth in cannabis only use after legalization. They also found a significant increase in people reporting both cannabis and antidepressant use.
The pattern among women attracted particular attention because women showed a stronger shift toward cannabis relative to antidepressants after legalization.
That finding needs context.
The study does not establish that individual women intentionally stopped taking prescribed antidepressants and replaced them with cannabis. It compared population level patterns across different periods rather than documenting a controlled treatment transition for each participant.
For operators, healthcare providers, researchers, and compliance teams, the broader signal still matters.
As cannabis becomes easier to access and more socially normalized, consumers may increasingly incorporate it into decisions involving mental health, prescription medication, sleep, stress, mood, and self directed care.
Why combined cannabis and antidepressant use matters
The increase in combined use may be just as important as the substitution headline.
Combined cannabis and antidepressant use increased from 1.3 percent before legalization to 5.5 percent afterward.
That creates an important healthcare communication issue.
Cannabis products vary significantly in THC content, CBD content, potency, dosage, frequency, formulation, and method of consumption. Antidepressants also include multiple medication classes with different effects and metabolic pathways.
Potential interactions therefore cannot be reduced to a single rule that applies to every patient.
Health Canada advises people using cannabis for medical purposes to inform healthcare professionals about prescription and nonprescription medications they take because cannabis can interact with other substances, including some medications used for mental health conditions.
The practical challenge is disclosure.
A person purchasing cannabis from an adult use retailer may not think of the product as something that needs to be discussed with a physician or pharmacist.
At the same time, a healthcare provider may not know that a patient has started using cannabis unless the patient mentions it.
That creates a gap between legal consumer access and clinical medication management.
Why medical claims are the real test
Cannabis operators should not turn this study into a claim that cannabis treats depression or safely replaces antidepressants.
The research does not establish either conclusion.
Researchers measured changes in reported cannabis and antidepressant use across the periods before and after legalization. They did not conduct a clinical trial demonstrating that cannabis was safer, more effective, or medically appropriate as a replacement for antidepressant treatment.
That distinction matters for websites, product descriptions, retail conversations, advertising, social media, testimonials, educational materials, and influencer content.
Consumers may describe personal experiences involving mood, stress, anxiety, sleep, or depression.
Individual experiences do not automatically support broader therapeutic claims about a cannabis product.
Operators should maintain a clear line between providing factual product information and providing medical treatment guidance.
Retail employees should know that they should not advise consumers to stop or reduce prescribed medications. Marketing teams should review health related claims carefully. Medical cannabis businesses should maintain appropriate clinical and regulatory review processes.
The more consumers incorporate cannabis into health related decisions, the more important those boundaries become.
Why operators and healthcare providers need readiness
Legal access can increase cannabis use without necessarily increasing communication between patients and healthcare professionals.
That creates pressure throughout the system.
Retailers need staff who understand the limits of their role when consumers ask questions involving antidepressants or mental health treatment.
Medical cannabis companies need educational materials that distinguish emerging research from established clinical evidence.
Compliance teams should review product claims, websites, testimonials, social posts, advertising, and educational content for statements that could imply unsupported treatment outcomes.
Healthcare professionals need complete medication histories that include cannabis use when appropriate.
Researchers also need better information about cannabinoid content, dosage, product type, frequency, prescription medication use, treatment history, and patient outcomes to understand why these population patterns are changing.
Operators should also be careful with headlines.
Saying women became more likely to use cannabis relative to antidepressants after legalization is different from saying researchers proved women abandoned antidepressants because cannabis became legal.
The first reflects the observed population pattern.
The second would go beyond what the research established.
If you need to organize health related marketing, product education, staff guidance, adverse event procedures, and insurance records, use the Puro Risk intake form to identify weak points before consumer health behavior creates additional compliance or liability exposure.
Conclusion
The Canadian research adds an important layer to the discussion around legalization, cannabis access, and mental health treatment.
Cannabis only use increased from 7.2 percent to 14.9 percent between the periods before and after legalization, while combined cannabis and antidepressant use increased from 1.3 percent to 5.5 percent.
Women showed a particularly strong increase in cannabis use relative to antidepressant use.
Those findings deserve attention, but they should not be interpreted as proof that cannabis is an effective replacement for antidepressants or that legalization directly caused individual patients to discontinue prescribed treatment.
The bigger lesson is about changing behavior.
Legalization can affect how consumers incorporate cannabis into decisions involving mental health, prescription medication, stress, mood, sleep, and self directed care.
For operators, healthcare providers, compliance teams, researchers, and patients, that creates a stronger need for accurate education, responsible product communication, clinical disclosure, and clear limits around medical claims.
Educational note: This article is for education only and is not legal, regulatory, medical, healthcare, pharmaceutical, mental health, product safety, licensing, financial, investment, or insurance advice. Cannabis should not be used to start, stop, replace, reduce, or modify prescription antidepressant treatment without guidance from a qualified healthcare professional. Potential risks and interactions depend on the medication, cannabis product, dose, frequency, individual health history, and other factors.
What to do this week
• Review product descriptions, websites, social content, and educational materials for unsupported depression, anxiety, antidepressant replacement, or other mental health treatment claims
• Train retail and customer facing teams not to advise consumers to stop, reduce, replace, or modify prescription medications
• Review patient education materials so they encourage appropriate conversations with qualified healthcare professionals when cannabis and prescription medications are used together
• Identify testimonials, influencer content, customer stories, or marketing language that could unintentionally be interpreted as medical treatment claims
• Review adverse event, product complaint, escalation, and documentation procedures for situations involving cannabis and prescription medication use
• Build a short internal memo on mental health claims, cannabis and antidepressant use, patient education, clinical guidance, and product liability risk
FAQ
What did the Canadian study find?
Researchers found that cannabis only use increased from 7.2 percent to 14.9 percent and combined cannabis and antidepressant use increased from 1.3 percent to 5.5 percent between the periods before and after legalization.
Were women more likely to use cannabis instead of antidepressants?
Women showed a significantly higher relative likelihood of cannabis use compared with antidepressant use after legalization. That is a population level association and does not prove that individual women intentionally stopped antidepressants and replaced them with cannabis.
Did the study prove cannabis can replace antidepressants?
No. The research examined patterns of cannabis and antidepressant use. It did not establish cannabis as an effective or clinically appropriate replacement for antidepressant medication.
How large was the study?
Researchers analyzed data from 20,498 Ontario adults age 18 and older collected between 2013 and 2023.
Can cannabis interact with antidepressants?
Potential interactions can occur, but their significance depends on the antidepressant, cannabis product, cannabinoid content, dose, frequency, method of consumption, individual health factors, and other medications. Patients should discuss cannabis use with a qualified healthcare professional.
What is the biggest operator takeaway?
Legalization can change how consumers use cannabis alongside healthcare. Operators need stronger boundaries around medical claims, better staff education, accurate product communication, and clear procedures for situations involving prescription medications.
What this means for operators
Cannabis business news can quickly become an insurance, compliance, contract, renewal, or claims issue. If this topic could affect your operation, review your insurance setup before pressure shows up from a landlord, lender, carrier, contract partner, regulator, or claim.
Clinician reviewing cannabis and antidepressant use with female patient
You might also like
SOURCES
International Cannabis Business Conference, Women More Likely To Substitute Cannabis For Antidepressants Post Legalization
Substance Use & Addiction Journal, Cannabis and Antidepressant Use During the Periods Before and After Cannabis Legalization in Ontario, Canada: 2013 to 2023
https://journals.sagepub.com/doi/abs/10.1177/29767342261462867
Health Canada, Cannabis for Medical Purposes: General Information
Health Canada, Information for Health Care Professionals: Cannabis and Cannabinoids
Canadian research found cannabis only use and combined cannabis and antidepressant use increased after legalization, with women showing a particularly strong shift toward cannabis relative to antidepressant use. The findings raise questions around patient education, medication interactions, mental health product claims, clinical guidance, and responsible cannabis access.